nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

BACKGROUND: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yardley, D A, Coleman, R, Conte, P, Cortes, J, Brufsky, A, Shtivelband, M, Young, R, Bengala, C, Ali, H, Eakel, J, Schneeweiss, A, de la Cruz-Merino, L, Wilks, S, O’Shaughnessy, J, Glück, S, Li, H, Miller, J, Barton, D, Harbeck, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096741/
https://www.ncbi.nlm.nih.gov/pubmed/29878040
http://dx.doi.org/10.1093/annonc/mdy201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096741/
https://www.ncbi.nlm.nih.gov/pubmed/29878040
http://dx.doi.org/10.1093/annonc/mdy201

Ejemplares similares